Program
GT737
A development code. Also written as “GT737 Injection”.
Its studies are mostly in Leukemia, Myeloid, Acute, led by Grit Biotechnology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Grit Biotechnology | 11 open or running | early phase 1since Jun 22, 2026 | Jun 22, 2026 | Jun 2030early phase 1 · NCT07676006 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 22, 2026First study: early phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT07676006 · 36 planned · China
Ahead
- Jun 2030Primary completion: early phase 1 study in Leukemia, Myeloid, AcuteNCT07676006
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07676006Leukemia, Myeloid, Acute · China | Early 1 | Not yet recruiting | Jun 2030 | 36 |
How it is read
Names in the registry
- “GT737 Injection”, 1 entry
Codes read as this program: GT737.
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.